Ed Feener
Founder at KALVISTA PHARMACEUTICALS, INC.
Net worth: 764 280 $ as of 2024-04-29
Ed Feener active positions
| Companies | Position | Start | End |
|---|---|---|---|
| KALVISTA PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2016-10-31 | - |
| Founder | 2004-03-25 | - | |
KalVista Pharmaceuticals Ltd.
 KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | Founder | 2010-12-31 | - |
| Corporate Officer/Principal | 2010-12-31 | - |
Career history of Ed Feener
Former positions of Ed Feener
| Companies | Position | Start | End |
|---|---|---|---|
| Harvard Medical School | Corporate Officer/Principal | 1989-06-30 | 2016-09-30 |
Training of Ed Feener
| Boston University | Doctorate Degree |
Statistics
International
| United States | 4 |
| United Kingdom | 2 |
Operational
| Founder | 2 |
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| KALVISTA PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Ed Feener
- Experience
